10 completed, 6 terminated, 2 active not recruiting, 1 recruiting. 19 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 10, Terminated 6, Active not recruiting 2, Recruiting 1 |
| Phase 2 | 6 | Terminated 3, Active not recruiting 1, Completed 1, Recruiting 1 |
Follow capmatinib: new trials by email Literature Review of capmatinib trials Research Report on capmatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Capmatinib, Amivantamab - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 57 | 2022-12-13 | 2026-09-25 |
| Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test Neratinib, Capmatinib - Metastatic Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 10 | 2022-08-18 | 2025-06-11 |
| Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation Capmatinib, Trametinib - Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer | Phase 1 | Terminated | Collin Blakely | 3 | 2022-08-10 | 2024-06-11 |
| Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). spartalizumab, LAG525, NIR178 - Triple Negative Breast Cancer (TNBC) | Phase 1 | Terminated | Novartis Pharmaceuticals | 64 | 2019-01-31 | 2025-05-18 |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC EGF816, trametinib, ribociclib - EGFR-mutant Non-small Cell Lung Cancer | Phase 1 | Active not recruiting | Novartis Pharmaceuticals | 105 | 2018-01-29 | 2026-01-16 |
| A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. INC280 - cMET Dysegulation Advanced Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 36 | 2016-12-14 | 2020-12-19 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC Spartalizumab, Capmatinib - Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 89 | 2016-06-15 | 2023-07-03 |
| A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors INC280, Midazolam, Caffeine - cMET-dysregulated Advanced Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 37 | 2015-12-10 | 2020-12-10 |
| A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors INC280, digoxin, rosuvastatin - cMET-dysregulated Advanced Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 32 | 2015-12-08 | 2020-12-10 |
| INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme INC280, bevacizumab - Glioblastoma Multiforme, Gliosarcoma | Phase 1 | Completed | SCRI Development Innovations, LLC | 65 | 2015-09-22 | 2023-09-21 |
| INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function INC280 - Hepatic Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 31 | 2015-06-12 | 2020-12-10 |
| Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. Capmatinib, Nazartinib - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 177 | 2015-01-13 | 2023-06-18 |
| Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy INC280, cetuximab - Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 13 | 2014-07-28 | 2019-01-22 |
| Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma INC280, Buparlisib - c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 43 | 2014-01-09 | 2018-05-30 |
| INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer INC280, erlotinib hydrochloride - Recurrent Non-small Cell Lung Cancer | Phase 1 | Completed | University of California, Davis | 35 | 2013-08-27 | 2021-10-13 |
| Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors INC280 - Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 131 | 2012-02-29 | 2020-12-19 |
| A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors INC280 - Advanced Solid Tumor | Phase 1 | Completed | Novartis Pharmaceuticals | 44 | 2012-02-01 | 2020-12-19 |
| A Dose-escalation Study in Subjects With Advanced Malignancies INCB028060 - Solid Tumor, Advanced Cancer | Phase 1 | Completed | Incyte Corporation | 45 | 2010-01-01 | 2017-11-22 |
Carcinoma, Non-Small-Cell Lung (5) · Glioblastoma (3) · Colorectal Neoplasms (2) · Gliosarcoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Laryngeal Diseases (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Rectal Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Novartis Pharmaceuticals (12) · Collin Blakely (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Incyte Corporation (1) · Janssen Research & Development, LLC (1) · M.D. Anderson Cancer Center (1) · SCRI Development Innovations, LLC (1) · University of California, Davis (1)
United States (15) · Italy (10) · Spain (10) · Germany (8) · France (7) · Canada (6) · Netherlands (5) · United Kingdom (5) · Hong Kong (4) · Singapore (4) · South Korea (4) · Taiwan (4) · Australia (3) · Denmark (3) · Japan (3)
Birgit Geoerger, MD (1) · Collin M Blakely, MD, PhD (1) · Karen Kelly (1) · Kent C. Shih, M.D. (1) · Lance Leopold (1) · Rachel Layman (1)
PMID 26825170, PMID 31538815, PMID 31776899, PMID 31778267, PMID 32240796, PMID 32410080, PMID 33892407, PMID 34046915, PMID 34053700, PMID 34347542, PMID 34543871, PMID 35292802, PMID 38617599, PMID 38986421, PMID 41838385, PMID 42686334
2014 (2), 2016 (2), 2015 (1), 2018 (1), 2023 (1), P30CA093373 (1)